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Background: A Krukenberg tumour (KT) is defined as an ovarian metastasis from a gastrointestinal adenocarcinoma
and suggests a terminal condition. This study aimed to identify the prognostic factors affecting the survival of
patients with KTs of colorectal origin who receive cytoreductive surgery.
Methods: Medical records of patients who had received cytoreductive surgery and had been pathologically
diagnosed with KT of colorectal origin in two centres were reviewed. Information about the patients’
clinicopathological features and follow-up visit were collected. Factors influencing patient survival were analysed.
Results: Fifty-seven patients were included in this study. The median survival time was 35 months. Five-year overall
survival was 25%. Patients who had recurrence 2 years after resection of the primary tumour, achieved complete
cytoreduction, had metastases confined to the pelvis, had no lymph node involvement, and received systemic
chemotherapy had a significantly longer median survival than those who had recurrence at the same time as
resection of the primary tumour (P = 0.027), received incomplete cytoreduction (P < 0.001), had metastases beyond
the pelvis (P < 0.001), had lymph node involvement (P = 0.011), and did not receive systemic chemotherapy (P = 0.
006) on log-rank test. Less extensive metastatic disease, achievement of complete cytoreduction, and use of
systemic chemotherapy were significantly associated with improved prognosis on multivariate analysis.
Conclusions: Cytoreductive surgery may confer survival benefits in patients with KTs of colorectal origin who attain
complete cytoreduction and whose metastases are confined to the pelvis and when combined with active systemic
chemotherapy.
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Krukenberg tumours (KTs) are defined by the World
Health Organization as ovarian carcinomas characterised
by the presence of stromal involvement, mucin-producing
neoplastic signet ring cells, and ovarian stromal sarcoma-
toid proliferation [1]. The term has also been applied to
metastatic ovarian tumours originating from gastrointes-
tinal adenocarcinomas. Up to 30% of ovarian malignancies
are in fact metastatic tumours [2, 3], with the stomach, col-
orectum, and breast being amongst the most common sites* Correspondence: guj@educationcmac.com
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The presence of KTs appears to indicate extensive ma-
lignant spread within the abdominal cavity. Indeed, the
prognosis for KTs of colorectal origin is so poor that
most patients die within 1 year after diagnosis of ovarian
metastasis. Chemotherapeutic drugs offering improved
tumour response rates in colorectal malignancies gener-
ally have low antineoplastic activity in the ovaries, which
act as a sanctuary for cancer cells. Surgical intervention
may therefore represent a reasonable alternative for the
management of ovarian metastatic disease that is in-
sensitive to these agents.
Nevertheless, the role of surgical resection remains
controversial in patients with KTs of colorectal origin inle is distributed under the terms of the Creative Commons Attribution 4.0
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surgery, low tumour resectability rates, and a high risk
of surgical complications. Some studies have shown that
resection of metastatic tumours can prolong survival [6,
7], whilst others have found that aggressive surgical ther-
apy offers no benefit for patients with KTs [8, 9]. In this
study, we aimed to identify the prognostic factors affect-
ing the survival of patients with KTs of colorectal origin
who receive cytoreductive surgery.
Methods
Patients with a documented diagnosis of malignant neo-
plasm of the colon, rectum, or ovary between 1994 and
2013 were identified from the medical records of the
Capital Medical University Cancer Centre and the
Beijing Cancer Hospital. Inclusion criteria for this study
included (a) having a confirmed pathological diagnosis
of KT of colorectal origin not caused by peritoneal seed-
ing and (b) receiving surgical resection of metastatic tu-
mours. Exclusion criteria included (a) the absence of
surgery or histological proof of KT and (b) the validation
of an ovarian non-adenocarcinoma metastasis.
All operative records were reviewed, and data pertaining
to the primary tumour and ovarian metastatic tumours
were collected. These included the main clinical symptoms;
the timing of ovarian metastasis (classified as synchronous
[detected within 1 year of the primary colorectal cancer
diagnosis] or metachronous [detected after more than
1 year]); the extent of surgery (classified as minimal [includ-
ing salpingo-oophorectomy or oophorectomy only on the
macroscopically abnormal side or bilateral salpingo-
oophorectomy or oophorectomy] or extensive [including
all types of more extensive resections for metastatic tu-
mours such as total abdominal hysterectomy plus bilateral
salpingo-oophorectomy, total abdominal hysterectomy plus
bilateral salpingo-oophorectomy plus omentectomy, and/or
bilateral pelvic and para-aortic lymphadenectomy and/or
resection of involved organs]); the completeness of cytore-
duction (CC0, no macroscopic residual tumour; CC1, max-
imal diameter of residual tumour <2.5 mm; CC2, maximal
diameter of residual tumour ≥2.5 mm; CC0 and CC1 are
described as complete cytoreduction, CC2 as incomplete
cytoreduction); the extent of metastatic disease; patho-
logical parameters; follow-up information; and the systemic
chemotherapy received.
All patients had clinically detected masses in their
ovaries and had received cytoreductive surgery with
curative intent, performed by gastrointestinal surgeons
in collaboration with gynaecological oncologists, for pre-
sumed primary ovarian cancers due to difficulty in dif-
ferentiation at the time of laparotomy. Patients with
peritoneal seeding were additionally treated with early
postoperative intraperitoneal chemotherapy. Pathology
reports for all patients were reviewed by a pathologist,and the presence of metastatic ovarian cancer of colo-
rectal origin was confirmed. Follow-up time was calcu-
lated from the diagnosis of KT to December 2014.
Deaths were categorised as events; patients who were
still alive at the last follow-up were excluded.
Statistical analysis
Survival analysis was performed using Kaplan–Meier
plots and the difference in survival rates compared using
the log-rank test. Variables between groups were com-
pared using the chi-square test. The SPSS computer
package (version 15.0, SPSS Inc., Chicago, IL, USA) was
used in all analyses. Results were considered statistically
significant at P < 0.05, and a multivariate analysis by Cox
regression model was performed in which P values by
log-rank test were <0.1 in the univariate analysis.
Results
Fifty-seven patients who had undergone surgical resec-
tion and had been diagnosed pathologically with KTs of
colorectal origin were included in the study. Fifteen pa-
tients had KTs detected by gastrointestinal surgeons dur-
ing the course of the treatment for colorectal cancer.
Forty-two patients were initially treated by gynaecolo-
gists and received operations for ovarian masses, of
whom five had colorectal cancer detected during the op-
eration and 37 had histories of colorectal cancer resec-
tion. The median follow-up time was 42 months, and
the median survival was 35.0 ± 3.5 months (range 6–
64 months). Five-year overall survival was 25%.
Characteristics of primary colorectal cancers and KTs
The mean age at diagnosis of a primary colorectal cancer
was 48.2 ± 13.2 (range 23–73) years. The three most
common sites of occurrence of a primary adenocarcin-
oma were the sigmoid colon (19 [33.3%] patients), rec-
tum (11 [19.3%] patients), and ascending colon (nine
[15.8%] patients) (Table 1). Lymph node metastasis was
confirmed in 36 (63.2%) patients, and retroperitoneal
lymph nodes were involved in 16 (28.1%) patients. T3
invasion was seen in 21 (36.8%) patients and T4 in 36
(63.2%) patients.
The mean age at diagnosis of KT was 49.3 ± 13.3 (range
24–74) years; 32 (56.1%) patients were pre-menopausal
(Table 1). The median interval between the diagnosis of
KTand that of a primary colorectal cancer was 17 months.
The mean size of KT was 9.7 cm (range 2.2–22.0 cm).
Thirty-six (63.2%) patients had bilateral ovarian involve-
ment and 45 (78.9%) patients received bilateral oophorec-
tomy or salpingo-oophorectomy. Contralateral ovaries
with a normal appearance were not resected in 12 patients
due to patient preference. Minimal surgery was performed
on 17 patients (29.8%) whereas extensive surgery, includ-
ing total abdominal hysterectomy plus bilateral salpingo-






Age at diagnosis of primary colorectal carcinoma
<60 years 43 75.4
≥60 years 14 24.6
Primary tumour site
Sigmoid colon 19 33.3
Rectum 11 19.3
Ascending colon 9 15.8
Caecum colon 8 14.0
Transverse colon 5 8.8
Descending colon 3 5.3
Multiple sites 2 3.5
Tumour histology
Well differentiated 19 33.3
Moderately differentiated 21 36.8
Poorly differentiated 11 19.3
Undifferentiated 6 10.5
Depth of tumour invasion
T3 21 36.8
T4 36 63.2
Primary lymph node metastasis
Retroperitoneal lymph node metastasis 16 36.8
Non-retroperitoneal lymph node metastasis 20 35.1
None 21 28.1
Ovarian metastatic tumours
Age at diagnosis of ovarian metastases
<60 years 40 70.2





Ovarian mass 18 31.6
Abdominal pain 14 24.6
Abdominal distension 11 19.3
Incidentally discovered during operation 8 14.0
Irregular vaginal bleeding 6 10.5
Timing of ovarian metastasis
Synchronous 21 36.8
13–24 months 23 40.4
>24 months 13 22.8
Tumour size
≤10 cm 33 57.9
Table 1 Clinical features of 57 patients with KTs of colorectal
origin (Continued)


















Note: CC0 and CC1 are described as complete cytoreduction, CC2 as
incomplete cytoreduction
CC0 no macroscopic residual tumour, CC1 maximal diameter of residual
tumour <2.5 mm, CC2 maximal diameter of residual tumour ≥2.5 mm, Movary
ovary-only metastasis, M1 metastasis confined to the pelvis, M2 metastasis be-
yond the pelvis
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eral salpingo-oophorectomy plus omentectomy, and/or bi-
lateral pelvic and para-aortic lymphadenectomy and/or
resection of other involved organs, was performed on 40
patients (70.2%).
Complete cytoreduction including CC0 and CC1 was
achieved in 42 (73.7%) patients. Ovary-only metastases
(Movary) were seen in 28 (49.1%) patients, and metastases
beyond the ovaries were seen in 29 (50.9%) patients. The
latter were confined to the pelvis (M1) in 14 (24.6%) pa-
tients and extended beyond the pelvis (M2) in 15
(26.3%) patients (Table 1).
Amongst patients with Movary or M1, 28 (100%) and
eight (57.1%) patients, respectively, received complete
cytoreduction. For those with M2, complete cytoreduc-
tion was achieved in six patients (40%). Nine (15.8%) pa-
tients had postoperative complications, six of whom had
metastases beyond the pelvis. Severe complications were
seen in three (5.3%) patients (two with an intestinal fis-
tula; one with respiratory complications); all of whom
had metastases beyond the pelvis and were >60 years of
age.
Thirty-four (59.6%) patients received postoperative
chemotherapy (Table 1). All adjuvant chemotherapeutic
regimens were fluorouracil-based, generally including
Table 2 Univariate analysis of overall survival in patients with





Age at diagnosis of KT 0.979
<60 years 36 27.546, 44.454
≥60 years 31 26.394, 35.606
Menses 0.425
Pre-menopausal 35 27.302, 42.698
Post-menopausal 38 26.016, 49.984
Timing of ovarian metastases 0.027
Synchronous 31 3.592, 58.408
13–24 months 35 28.196, 41.804
>24 months 54 37.622, 70.378
Tumour size 0.256
≤10 cm 36 30.511, 41.489
>10 cm 20 2.402, 37.598
Status of ovarian involvement 0.570
Unilateral 35 25.783, 44.217
Bilateral 36 25.828, 46.172
Extent of metastatic disease <0.001
Movary 54 35.028, 72.972
M1 35 20.868, 49.132
M2 13 10.608, 15.392
Extent of surgery 0.224
Minimal 32 12.493,51.507
Extensive 38 29.071, 46.929
Completeness of cytoreduction <0.001
CC0 56 46.082, 58.200
CC1 28 10.066, 45.934
CC2 13 7.951, 18.049
Systemic chemotherapy 0.006
Yes 47 34.992, 59.008
No 30 8.932, 51.068
Depth of tumour invasion 0.117
T3 39 33.234, 44.766
T4 30 15.296, 44.704







None 39 27.484, 50.516
Note: CC0 and CC1 are described as complete cytoreduction, CC2 as
incomplete cytoreduction
CC0 no macroscopic residual tumour, CC1 maximal diameter of residual
tumour <2.5 mm, CC2 maximal diameter of residual tumour ≥2.5 mm, Movary
ovary-only metastasis, M1 metastasis confined to the pelvis, M2 metastasis be-
yond the pelvis
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irinotecan thereafter. Two patients received bevacizu-
mab for 4–6 cycles; however, this strategy was later
abandoned because of cost. Early postoperative intraper-
itoneal chemotherapy with 5-fluorouracil, mitomycin,
cisplatin, or irinotecan was administered for 1–5 cycles
in all patients with peritoneal seeding.
Factors affecting patients’ overall survival (univariate
analysis)
Five variables were closely associated with overall survival
in the univariate analysis: the timing of ovarian metastasis,
the presence of lymph node metastasis, the extent of
metastatic disease, the completeness of cytoreduction, and
the use of systemic chemotherapy (Table 2).
Survival significantly increased with the disease-free
interval between the diagnosis of the primary colorectal
cancer and that of the KT (P = 0.027), mainly due to the
survival difference between patients diagnosed with KT
more than 2 years after surgery for removal of a primary
tumour and patients with synchronous ovarian metasta-
ses by pairwise comparison in the log-rank test
(54 months vs 31 months, P = 0.008).
Patients with retroperitoneal lymph node metastases
had a shorter survival time than those with negative
lymph node metastases (18 months vs 44 months, P =
0.001) but had a comparable survival time than those
with non-retroperitoneal lymph node metastases (P =
0.373). By pairwise comparison using the log-rank test,
patients with Movary survived longer than those with M1
(P = 0.001). Subsequently, patients with M1 survived lon-
ger than those with M2 (P = 0.014).
The degree of cytoreduction was associated with a sig-
nificant difference in overall survival (CC0:CC1, 56 months
vs 28 months, P < 0.001; CC0:CC2, 56 months vs
13 months, P < 0.001; CC1:CC2, 28 months vs 13 months,
P = 0.014). Patients attaining CC0 and CC1 after surgery
were considered to have complete cytoreduction; these
patients had significantly improved survival compared
with those with incomplete cytoreduction (39 months vs
13 months, P < 0.001), although the difference did not
reach significance in the M2 subgroup by stratified ana-
lysis (P = 0.253).
The median survival in patients who received systemic
chemotherapy was significantly longer than that in pa-
tients who did not (47 months vs 30 months, P = 0.006).
Factors affecting patients’ overall survival (multivariate
analysis)
A multivariate analysis was performed on five variables:
the time to ovarian metastasis, the presence of lymph
node metastases, the extent of metastatic disease, the
completeness of cytoreduction, and the use of systemic
chemotherapy.
Fig. 2 Kaplan–Meier survival curves showing the effect of the extent
of metastatic disease on patients with Krukenberg tumours of
colorectal origin (P < 0.001, log-rank test). Movary ovary-only metasta-
sis, M1 metastasis confined to the pelvis, M2 metastasis beyond
the pelvis
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(HR) 0.135; P = 0.001) (Fig. 1), less extensive metastatic
disease (HR, 0.287; P = 0.029) (Fig. 2), and administra-
tion of systemic chemotherapy (HR, 0.345; P = 0.012)
(Fig. 3) were all independently and strongly associated
with improved overall survival. Lymph node metastases
had a tendency to be associated with poor prognosis
with marginal statistical significance (P = 0.061).
Discussion
Overall, KTs account for 30–40% of metastatic ovarian tu-
mours [10, 11]. The actual incidence of KTs, as seen dur-
ing autopsy and prophylactic oophorectomy, is much
higher than that observed in the clinical setting. The ovary
is the second most common intra-abdominal solid organ
site of metastasis of colorectal cancer after the liver. At
our two centres, KTs occurred in as few as 4.8% of women
diagnosed with colorectal cancer during the study period.
Women with clinically suspected KTs but who did not
undergo surgery were not included in this study.
As shown in previous publications [12, 13], patients in
this study were diagnosed with KTs at a median age of
49 years. More than half (32/57, 56.1%) were pre-
menopausal, which may be partly because the blood sup-
ply to the pre-menopausal ovary increases the risk of
metastatic disease [14]. We thus recommend that atten-
tion be paid to the ovaries of women with colorectal
cancer, particularly those of pre-menopausal women,
both at the time of surgery and during follow-up.
Consistent with reports that the incidence of bilateral
ovarian metastases ranges from 57 to 70% [13, 15],Fig. 1 Kaplan–Meier survival curves showing the effect of
cytoreduction on patients with Krukenberg tumours of colorectal
origin (P < 0.001, log-rank test)bilateral ovarian involvement was seen in 63.2% (36/57)
of the cohort studied. The American Society of Colon
and Rectal Surgeons [16] recommends that oophorec-
tomy be performed in patients suspected or known to
have ovarian involvement, either by direct extension or
metastasis. If one ovary is found to be positive forFig. 3 Kaplan–Meier survival curves showing the effect of systemic
chemotherapy on patients with Krukenberg tumour of colorectal
origin (P = 0.006, log-rank test)
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performed despite limited supporting data [17, 18] be-
cause the contralateral ovary has an equal probability of
metastatic involvement and may already harbour micro-
scopic metastases.
The prognosis of KTs is generally poor, and in particular,
patients with KTs of gastrointestinal origin survive an
average of 7–17 months on palliative treatment [19, 20].
Actually considered a potential pattern for peritoneal
seeding by Ishii et al. [21], KTs indicate a terminal condi-
tion. In the present study, median survival was longer at
35 months (range 6–64 months), possibly as a result of
cytoreductive surgery. Death eventually resulted from
intra-abdominal tumour progression that was unrespon-
sive to available drugs.
Being a metastatic disease with an inherently poor out-
come, surgeons tend to forgo surgical resection for KTs.
When surgery is performed, it is frequently intended as
palliative care. In contrast, complete surgical resection
of metastatic tumours is currently conducted for cura-
tive reasons for liver metastasis of colorectal cancer ori-
gin [22]. In the current study, cytoreductive surgery was
shown to be a significant prognostic factor, and patients
with complete cytoreduction achieved a drastic improve-
ment in survival compared with those with incomplete
cytoreduction. The greatest benefit of surgery was seen
in patients with CC0 (5-year survival, 46.6%; median
overall survival, 56 months). Patients with CC1 also sur-
vived longer than those with CC2.
Rayson et al. [23] and Morrow and Enker [24] previ-
ously drew the same conclusion: complete metastasect-
omy could result in prolonged survival compared with
palliative surgery in patients with KTs of colorectal can-
cer origin. Additionally, a study in Japan reported that
two patients with KTs of colorectal cancer origin who
were treated with pelvic exenteration both survived for
more than 5 years [25], suggesting that surgery with the
intention of removing all gross disease can result in sig-
nificantly improved survival. Complete cytoreduction
plays an important role in patients with KTs of colorec-
tal origin by decreasing the residual tumour burden to
an acceptable level in combination with the periopera-
tive use of effective chemotherapeutic agents and new
targeted drugs.
Multivariate analysis confirmed the extent of meta-
static disease as another indicator of worse prognosis in
the present study. Survival was reduced when more sites
in the abdominal cavity were invaded by metastatic dis-
ease; patients with M2 had the poorest prognosis com-
pared with patients with Movary and M1 and presented
with a 5-year overall survival rate of zero. As Miller
et al. reported [14], patients with and without peritoneal
seeding had a striking difference in overall survival at
5 years (22.6 and 53%, respectively).Moreover, the extent of metastatic disease was a major
determinant of benefit from surgical treatment. In pa-
tients with metastases confined to the pelvis, complete
cytoreduction can be achieved more easily compared
with those with metastases beyond the pelvis (86%:40%,
P = 0.002, chi-square test). In addition, metastasis be-
yond the pelvis was associated with a high risk of severe
complications, which caused the postoperative death of
two patients (not included in this study).
We agree with Elias and colleagues [26] that early sur-
gical intervention for the detection of a small volume of
metastasis may optimise survival benefits. Patients with
M2, who usually have a poorer general status, are not
likely to gain any survival benefit but are prone to severe
surgical complications if cytoreductive surgery is under-
taken. In our opinion, these factors must be considered
before planning surgical intervention for patients with
M2.
Systemic chemotherapy was demonstrated as an inde-
pendent factor of better prognosis in a Cox regression
model. Patients who received systemic chemotherapy
showed significant improvement in survival compared
with those who did not. However, from a stratified
Kaplan–Meier analysis, a significant survival benefit was
shown only in patients with lymph node metastasis, for
which systemic chemotherapy was more intensively
recommended.
Limitations of this study included a small sample size,
which was influenced by the rarity of the occurrence of
KTs and surgeons’ experience, patients’ desire to receive
aggressive surgery for its potential benefits, and its retro-
spective design. However, the study offers important
insight into the factors affecting the prognosis of pa-
tients with KTs of colorectal origin who receive cytore-
ductive surgery.Conclusions
In conclusion, surgery with curative intent should not
easily be abandoned in patients with KTs even if metas-
tases extend beyond the ovaries. Comprehensive pre-
operative evaluation of the extent of metastatic disease is
crucial for treatment planning. Improved survival is pos-
sible in patients who attain complete cytoreduction,
whose metastases are confined to the pelvis, and who re-
ceive active chemotherapy. Future studies should focus
on the potentially synergistic effect of surgery and the
perioperative administration of cytotoxic and molecular
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